Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant tre...

Descripción completa

Detalles Bibliográficos
Autores principales: De Simone, Clara, Perino, Francesca, Caldarola, Giacomo, D’Agostino, Magda, Peris, Ketty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Immuno-Mediated Diseases And Comorbities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536537/
https://www.ncbi.nlm.nih.gov/pubmed/27683143
http://dx.doi.org/10.1177/0300060515593250
_version_ 1783254027565268992
author De Simone, Clara
Perino, Francesca
Caldarola, Giacomo
D’Agostino, Magda
Peris, Ketty
author_facet De Simone, Clara
Perino, Francesca
Caldarola, Giacomo
D’Agostino, Magda
Peris, Ketty
author_sort De Simone, Clara
collection PubMed
description Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.
format Online
Article
Text
id pubmed-5536537
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55365372017-10-03 Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports De Simone, Clara Perino, Francesca Caldarola, Giacomo D’Agostino, Magda Peris, Ketty J Int Med Res Immuno-Mediated Diseases And Comorbities Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects. SAGE Publications 2016-09-28 2016-09 /pmc/articles/PMC5536537/ /pubmed/27683143 http://dx.doi.org/10.1177/0300060515593250 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Immuno-Mediated Diseases And Comorbities
De Simone, Clara
Perino, Francesca
Caldarola, Giacomo
D’Agostino, Magda
Peris, Ketty
Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
title Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
title_full Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
title_fullStr Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
title_full_unstemmed Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
title_short Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
title_sort treatment of psoriasis with etanercept in immunocompromised patients: two case reports
topic Immuno-Mediated Diseases And Comorbities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536537/
https://www.ncbi.nlm.nih.gov/pubmed/27683143
http://dx.doi.org/10.1177/0300060515593250
work_keys_str_mv AT desimoneclara treatmentofpsoriasiswithetanerceptinimmunocompromisedpatientstwocasereports
AT perinofrancesca treatmentofpsoriasiswithetanerceptinimmunocompromisedpatientstwocasereports
AT caldarolagiacomo treatmentofpsoriasiswithetanerceptinimmunocompromisedpatientstwocasereports
AT dagostinomagda treatmentofpsoriasiswithetanerceptinimmunocompromisedpatientstwocasereports
AT perisketty treatmentofpsoriasiswithetanerceptinimmunocompromisedpatientstwocasereports

Ejemplares similares